The growth of Viagra and its influence on the pharmaceutical landscape presents a complex question for investors. While the first sales statistics were astounding, the patent has lapsed, leading to a wave of generic alternatives that are reducing revenue. Furthermore, the market is facing issues related to demographic trends and changing healthcare